KUGIMIYA, T., FUJISAWA, M., SUWA, K., YAMAMURA, H., MINOHARA, K. and KASAMA, T. Effects of Ortho-Iodo-Sodium Benzoate (OISB) on Oxygen-Hemoglobin Affinity and Its Relation to Plasma Concentrations in Dogs. Tohoku J. exp. Med., 1982, 136 (1), [35] [36] [37] [38] [39] [40] [41] Effects of orth~,-iodo-s' dium benzoate (OISB) on oxygenhemoglobin affinity were studied in unanesthetized beagles with simultaneous measurement o f its plasma concentrations. Oxygen-hemoglobin affinity changes correlated well with the plasma concentrations of the drug. Intravenous administration of 100 mg/kg of OISB increased P50 significantly from the control value of 28.6±0.8 mmHg to 29.5±0.7 mmHg and 30.0±0.5 mmHg, 5 min and 30 min after the infusion, respectively. P50 gradually decreased thereafter, and after 1 hr period, elevation was no longer significant. Administration of 200 mg/kg of OISB caused a significant increase in P50 from the control of 29.3±0.3 mmHg to 30.5±0.4 mmHg, 31.1±0.3 mmHg, 31.1±0.3 mmHg and 30.5±0.5 mmHg, at 5 min, 30 min, 1 hr and 3 hr, respectively. P50 elevation declined thereafter to control levels. Plasma concentrations of the drug reached its highest level 5 min after the administration and declined gradually thereafter. All significant elevations of P50 were accompanied by the plasma concentrations of the drug more than 200 ,cog/ml. Biological half-life of the drug was found to be about 5.5 hr.
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Ortho-iodo-sodium benzoate (OISB) was shown to influence the oxygenhemoglobin affinity and the oxyhemoglobin dissociation curves of the hemoglobin solution and of the intact red-cells (Layer 1975) . Litwin et al. (1976) reported in vivo effects of the drug given to intact dogs and showed a significant decrease in oxygen-hemoglobin affinity after single and multiple intravenous administrations, with no apparent detrimental effects except for an increase in serum lactate and pyruvate.
They made an assumption that the plasma concentration of OISB could be estimated by the dosage administered, and that 500 mg/kg of OISB given intravenously should result in a concentration of 185 mg/ 100 ml. Such an estimation, based on mathematical calculations, is vulnerable to an error in in vivo conditions, although it may yield a reasonably accurate estimate of in vitro values.
The changes in in vivo oxygen-hemoglobin affinity caused by OISB had better be described with regard to the plasma concentrations of this agent. We report here the effect of OISB on oxygen-hemoglobin affinity in intact dogs withh simultaneous measurement of plasma concentrations of this agent.
MATERIALS AND METHODS
OISB was prepared according to the method of Litwin et al. (1976) . Twelve unanesthetized beagles (body weight, 7.2 to 11.4 kg) were divided into two groups (6 each), and 100 mg/kg or 200 mg/kg of OISB was given intravenously as a single bolus injection into the animal.
Blood samples for measurements were obtained at pre-determined intervals (before OISB administration, 5 min, 30 min, l hr, 3 hr, 6 hr, 9 hr and 24 hr after the administration). For the 200 mg/kg group only, blood samples were taken one week after the injection. Each animal served as its own control. Hematocrit and hemoglobin, whole blood pH, Pco2, Pot and base excess were determined by standard laboratory procedures and were used for correction of measured P50's to the standard condition. Oxyhemoglobin dissociation curves (ODC) of whole blood were analyzed with a Hem-O-Scan (AMINCO). At least three curves were generated for each sample, P50's were read from the original curves, and then they were corrected to the standard condition (37°C; pH, 7.40; Pco2, 40 mmHg) according to the formula published previously (Kugimiya et al. 1979) .
Plasma concentration of OISB was measured as follows : Blood was centrifuged and plasma was separated. 25 ml of ether and 3 ml of 0.1 N HCl were added to 1 ml of the plasma, which was then shaked for 15 min and centrifuged at 3000 rpm for 10 min. 20 ml of upper organic phase, which contained OISB, was transferred into another container and was desiccated. The precipitate was dissolved into 1 ml of methyl alcohol, and then 5,il of the solution was injected into the liquid chromatogram (Hitachi 635), using a Licrosorb RP 18 chromatographic column (4x250mm). Water-acetonitrile (4:1/ v/v) was used at the flow rate of 0.5 ml/min. OISB was detected with the spectrophotometer (Hitachi Model 200-10) at 230 nm UV. Plasma concentration of OISB was then calculated from a ratio to that of known amount of the drug by extrapolation.
Dogs were observed for any apparent acute or chronic detrimental side effects of OISB, such as retching, vomiting and other gross abnormal behaviors.
Statistical evaluation of the data was performed using Student's t-test.
RESULTS
OISB infusion was accepted without difficulty. All dogs not only survived the experiment, but showed no apparent detrimental effects nor abnormal behaviors. Tables 1 and 2 show the changes in the blood gas parameters and hematocrit values for the 100 mg/kg and the 200 mg/kg groups, respectively. None of them are significantly different from the control values.
Figs. 1 and 2 demonstrate the plasma concentrations of OISB following intravenous infusion of the agent. The plasma concentrations of the drug showed its highest value 5 min after the infusion in both groups and gradually decreased thereafter up to 24 hr. In the 200 mg/kg group, no OISB was detected in the plasma one week after the administration. Fig. 1 . Changes in the plasma concentration of 100 mg/kg group. Meanhs.n. The highest the injection and it declined thereafter.
OISB after intravenous injection concentration was obtained 5 min in the after
Pharmacokinetic analysis revealed elimination rate constants (Kel) of 0.129 hr-' and 0.119 hr-1 for the 100 mg/kg and the 200 mg/kg groups, respectively. Biological half-life was found to be about 5.5 hr for both groups (Table 3) .
In the 100 mg/kg group (Fig. 3) , P50 was significantly higher than control value (28.6±0.8 mmHg) at 5 min (29.5±0.7 mmHg) and 30 min (30.0±0.5 mmHg) of OISB infusion. P50 gradually declined thereafter, and after 1 hr period, elevation was no longer significant. Interestingly, although plasma OISB levels reached near zero at 24 hr, P50 showed slight elevation, though this was not statistically significant.
In the 200 mg/kg group (Fig. 4) , a significant increase in P50 from the control value continued till 3 hr after the infusion (control, 29.3±0.3 mmHg; 5 min, 30.5±0.4 mmHg ; 30 min, 31.1±0.3 mmHg ; 1 hr, 31.1±0.3 mmHg ; 3 hr, 30.5±0.5 mmHg). As in the 100 mg/kg group, P50 values showed slight elevation at 24 hr and 7 days, but they were again not statistically significant. Mean±s.D. Asterisk shows statistically significant difference from the control value. The greatest change in P10 was obtained half an hour after the OISB administration. Thereafter, P50 declined gradually. P50 remained increased at 24 hr but this was not statistically significant. Mean±s.D. Asterisk shows statistically significant difference from the control value. The highest elevation in P50 was obtained 30 min and 1 hr after the administration. Thereafter, P50 declined gradually to control value. At 24 hr and 7 days, P50's were slightly elevated, but these were not statistically significant. increase in P50 resulted from the plasma concentrations of OISB above 200 µg/ml. Litwin et al. (1976) showed persistent elevation of P50 after single infusion of 500 mg/kg of OISB for about one week. In our study, significant elevation of P50 lasted only for 3 hr by 200 mg/kg of OISB infusion and only half an hour by 100 mg/kg of OISB, and these elevations correlated well with the plasma concentrations of the drug. Plasma concentrations of OISB below 200 ug/ml did not seem to elevate P50 significantly.
It is somewhat puzzling why P50 elevation persisted for as long as a week in Litwin et al.'s study (1976) , while plasma concentrations of the drug declined rather rapidly in our study with the biological half-life of about 5.5 hr. This short effect of OISB on P50 is also mentioned by one of discussions in Litwin et al.'s paper (1977) , but again concentration was not measured. Even with 500 mg/kg dosage, it is difficult to imagine that OISB lingered in the plasma for as long as a week so as to have any significant effects on P5o.
Interestingly enough, however, P50 showed a tendency to remain higher than the control value even after the plasma concentrations of OISB reached near zero. Unknown factors other than OISB per se may be working in this phenomenon, and with a greater dosage of OISB such as 500 mg/kg, this effect might have been more pronounced in the study of Litwin et al. (1976) than in our study. This might have resulted in significant elevation of P50 in their study long after the administration.
Although OISB concentration in the plasma was highest 5 min after the injection, the greatest change in P50 in both groups appeared not 5 min but 30 min afterr the injection, though the differences between them were not statistically significant. This appears to contradict the report that OISB readily penetrates erythrocytic membranes (Layer 1975 ). The reason is not clear, but several speculations can be made. The binding of OISB with the plasm protein may delay the entry of OISB into the red blood cells. OISB may show its effect on oxyhemoglobin dissociation curve not only through its direct binding with hemoglobin but through some unknown metabolic influences, which may account for the delay. Further elucidation of the exact behavior of OISB in intact body is necessary. Litwin et al. (1976) chose the dosage of OISB of 500 mg/kg to obtain presumed plasma concentration of 185 mg/100 ml, which is 1850 ,~g/ml. 200 mg/kg of OISB administration resulted in a plasma concentration of 294 to 510 µg/ml. Although there is a little discrepancy between actual concentration and presumed one, their presumption was reasonably accurate. 
1)
2)
3)
4)
Ortho-Ido-Sodium Benzoate on Oxygen-Hemoglobin Affinity 41
